-
Je něco špatně v tomto záznamu ?
Kinetically guided neoadjuvant chemoradiotherapy based on 5-Fluorouracil in patients with locally advanced rectal cancer
J. Grim, M. Hroch, H. Miloš, J. Chládek, C. Jaroslav, J. Petera, P. Jiří, J. Martínková, M. Jiřina,
Jazyk angličtina Země Nový Zéland
Typ dokumentu klinické zkoušky, časopisecké články, práce podpořená grantem
NLK
ProQuest Central
od 2007-06-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2007-06-01 do Před 1 rokem
- MeSH
- chemoradioterapie MeSH
- fluoruracil aplikace a dávkování škodlivé účinky farmakokinetika MeSH
- intravenózní infuze MeSH
- kombinovaná terapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory rekta farmakoterapie metabolismus patologie radioterapie MeSH
- následné studie MeSH
- neoadjuvantní terapie MeSH
- prospektivní studie MeSH
- protinádorové antimetabolity aplikace a dávkování škodlivé účinky farmakokinetika MeSH
- protokoly protinádorové kombinované chemoterapie škodlivé účinky terapeutické užití MeSH
- senioři MeSH
- staging nádorů metody MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- práce podpořená grantem MeSH
BACKGROUND AND PURPOSE: This study estimated patients' early response following neoadjuvant chemoradiotherapy (CHRT) of locally advanced rectal cancer based on 5-fluorouracil (5-FU). The target was to achieve pathological complete response (pCR; residual disease-free stage) and toxicities of grade ≤2, using individual dosing predicted according to the steady-state plasma concentration (C ss) and pharmacokinetic parameters of 5-FU: the area under the time-concentration curve at steady state (AUC) and clearance (CL). PATIENTS AND METHODS: This open-label prospective study enrolled 33 adult patients treated with 5-FU administered as a continuous intravenous infusion over 4-5 weeks, as follows: in Group 1a (N = 6), the patients received a standard dose of 300 mg/m(2)/24 h. In Group 1b (N = 7), the patients were treated with an escalated dose of 400-1,000 mg/m(2)/24 h. In Group 2 (N = 20), the patients were given dosing kinetically guided in order to reach the target range of 5-FU C ss 50-100 µg/L. Tolerability was tested according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Radiotherapy was delivered with 10-15 MV photon beams at 1.8 Gy/fraction up to 50.4 Gy in 28 daily fractions for 5 days a week. Surgery followed 4-6 weeks after the completion of CHRT and clinical restaging. The pCR and residual tumour stage were evaluated using preoperative tumour downstaging in magnetic resonance, postoperative histopathological staging and tumour regression rate (residual disease). RESULTS AND CONCLUSION: The cumulative AUC of 5-FU (total exposure to the drug) correlated with cumulative 5-FU dose (r = 0.61; p < 0.001) and residual disease (r s = -0.53; p < 0.005). A higher target pCR rate was reached in patients individually treated (Group 2) who finished the whole 5-week CHRT. The individual daily dose needed to reach the target C ss should be >350 mg/m(2) (up to 600 mg/m(2)) provided that 5-FU metabolic ratio is within the range of 2.5-6 and the cumulative AUC5wks is within 50-100 mg·h/L.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16010662
- 003
- CZ-PrNML
- 005
- 20171219080826.0
- 007
- ta
- 008
- 160408s2015 nz f 000 0|engg|
- 009
- AR
- 024 7_
- $a 10.1007/s40262-014-0216-4 $2 doi
- 024 7_
- $a 10.1007/s40262-014-0216-4 $2 doi
- 035 __
- $a (PubMed)25503423
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a nz
- 100 1_
- $a Grim, Jiří $u Department of Oncology and Radiotherapy, University Hospital, Sokolská Street, 500 05, Hradec Králové, Czech Republic, grimj@lfhk.cuni.cz.
- 245 10
- $a Kinetically guided neoadjuvant chemoradiotherapy based on 5-Fluorouracil in patients with locally advanced rectal cancer / $c J. Grim, M. Hroch, H. Miloš, J. Chládek, C. Jaroslav, J. Petera, P. Jiří, J. Martínková, M. Jiřina,
- 520 9_
- $a BACKGROUND AND PURPOSE: This study estimated patients' early response following neoadjuvant chemoradiotherapy (CHRT) of locally advanced rectal cancer based on 5-fluorouracil (5-FU). The target was to achieve pathological complete response (pCR; residual disease-free stage) and toxicities of grade ≤2, using individual dosing predicted according to the steady-state plasma concentration (C ss) and pharmacokinetic parameters of 5-FU: the area under the time-concentration curve at steady state (AUC) and clearance (CL). PATIENTS AND METHODS: This open-label prospective study enrolled 33 adult patients treated with 5-FU administered as a continuous intravenous infusion over 4-5 weeks, as follows: in Group 1a (N = 6), the patients received a standard dose of 300 mg/m(2)/24 h. In Group 1b (N = 7), the patients were treated with an escalated dose of 400-1,000 mg/m(2)/24 h. In Group 2 (N = 20), the patients were given dosing kinetically guided in order to reach the target range of 5-FU C ss 50-100 µg/L. Tolerability was tested according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Radiotherapy was delivered with 10-15 MV photon beams at 1.8 Gy/fraction up to 50.4 Gy in 28 daily fractions for 5 days a week. Surgery followed 4-6 weeks after the completion of CHRT and clinical restaging. The pCR and residual tumour stage were evaluated using preoperative tumour downstaging in magnetic resonance, postoperative histopathological staging and tumour regression rate (residual disease). RESULTS AND CONCLUSION: The cumulative AUC of 5-FU (total exposure to the drug) correlated with cumulative 5-FU dose (r = 0.61; p < 0.001) and residual disease (r s = -0.53; p < 0.005). A higher target pCR rate was reached in patients individually treated (Group 2) who finished the whole 5-week CHRT. The individual daily dose needed to reach the target C ss should be >350 mg/m(2) (up to 600 mg/m(2)) provided that 5-FU metabolic ratio is within the range of 2.5-6 and the cumulative AUC5wks is within 50-100 mg·h/L.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a protinádorové antimetabolity $x aplikace a dávkování $x škodlivé účinky $x farmakokinetika $7 D000964
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
- 650 _2
- $a chemoradioterapie $7 D059248
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a fluoruracil $x aplikace a dávkování $x škodlivé účinky $x farmakokinetika $7 D005472
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a intravenózní infuze $7 D007262
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a neoadjuvantní terapie $7 D020360
- 650 _2
- $a staging nádorů $x metody $7 D009367
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a nádory rekta $x farmakoterapie $x metabolismus $x patologie $x radioterapie $7 D012004
- 655 _2
- $a klinické zkoušky $7 D016430
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Hroch, Miloš, $d 1976- $7 xx0076212
- 700 1_
- $a Chládek, Jaroslav
- 700 1_
- $a Petera, Jiří
- 700 1_
- $a Martínková, Jiřina
- 773 0_
- $w MED00001154 $t Clinical pharmacokinetics $x 0312-5963 $g Roč. 54, č. 5 (2015), s. 503-15
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25503423 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160408 $b ABA008
- 991 __
- $a 20171219081022 $b ABA008
- 999 __
- $a ok $b bmc $g 1114091 $s 935030
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 54 $c 5 $d 503-15 $i 0312-5963 $m Clinical pharmacokinetics $n Clin Pharmacokinet $x MED00001154
- LZP __
- $a Pubmed-20160408